Almudena Dominguez-Gonzalez

17, 5º, Moreto Street
Madrid, MD 28014, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons.

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons.

Journal: Rheumatology and therapy

Published: June 11, 2025

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.

Journal: PharmacoEconomics - open

Published: July 31, 2024

Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.

Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.

Journal: Revista clinica espanola

Published: April 11, 2023

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain.

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain.

Journal: Global & regional health technology assessment

Published: July 04, 2022

[Translated article] The Utility of long-Term Number Needed to Treat to Evaluate Interleukin 17 and 23 Inhibitor Therapies in the Treatment of Moderate to Severe Plaque Psoriasis.

[Translated article] The Utility of long-Term Number Needed to Treat to Evaluate Interleukin 17 and 23 Inhibitor Therapies in the Treatment of Moderate to Severe Plaque Psoriasis.

Journal: Actas dermo-sifiliograficas

Published: June 23, 2022

Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.

Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.

Journal: Nefrologia

Published: April 22, 2022

Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.

Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.

Journal: Vaccine

Published: August 03, 2021

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

Journal: Gynecologic oncology

Published: June 17, 2021

Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain.

Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain.

Journal: Advances in therapy

Published: April 21, 2021

Costs of the management of hemophilia A with inhibitors in Spain.

Costs of the management of hemophilia A with inhibitors in Spain.

Journal: Global & regional health technology assessment

Published: January 21, 2021

Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain.

Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain.

Journal: Global & regional health technology assessment

Published: November 30, 2020

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.

Journal: Journal of medical economics

Published: October 19, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026